Drug intelligence / Profile preview

NouvSight001

Development stage: Preclinical
Lead developer: iRegene Therapeutics
Modality: Cell Therapies
Administration: Ophthalmic

Overview

NouvSight001 is a novel ophthalmic product developed by iRegene Therapeutics, designed to treat retinal diseases. It is a first-of-its-kind allogeneic cell therapy derived from induced pluripotent stem cells (iPSC), utilizing iRegene's proprietary "AI + chemical induction" platform. The drug received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in March 2024, indicating its potential for addressing rare retinal conditions.

Beyond the preview

Go deeper on NouvSight001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NouvSight001.

Explore the full profile